UK Biobank Whole Genome Sequencing project
Together with deCODE in Iceland, the Sanger Institute will read and assemble the whole genome sequences of 500,000 UK Biobank volunteers. The Sanger Institute will sequence 225,000 whole human genomes.
This is one of the most ambitious sequencing efforts of whole human genomes ever undertaken. Sequencing will take place over 27 months, starting in September 2019. This builds on the ongoing success of the pilot programme, known as the Vanguard project, in which Sanger is sequencing 10 per cent of the cohort – 50,000 genomes of UK Biobank volunteers.
A dataset of this magnitude will be incredibly powerful for understanding the genetic architecture that contributes to diseases such as cancer, cardiovascular diseases, depression and dementia.
The £200m project is being funded by a collaboration between the government’s research and innovation agency, UK Research and Innovation (UKRI), Wellcome, Amgen, AstraZeneca, GlaxoSmithKline (GSK) and Johnson & Johnson*.
The first tranche of data is expected to comprise of up to 125,000 sequences, anticipated to be accessible to all in Spring 2021 and at the same time the 50,000 Vanguard sequences will be available.
The expectation is that sequence data for the entire cohort of UK Biobank participants would become generally accessible by early 2023.
* Contract entered by Janssen Biotech Inc., one of the Pharmaceutical Companies of Johnson & Johnson; collaboration facilitated by the Johnson & Johnson EMEA Innovation center in London, UK
High-Throughput DNA Sequencing
The High Throughput DNA sequencing team within DNA Pipelines Operations is a highly automated high throughput team specialising in producing libraries ...
Programmes and Facilities
The Human Genetics Programme is driving a step-change in our understanding of genetic causes and biological mechanisms of disease susceptibility and ...